Exelixis (EXEL) News Today $41.59 -0.19 (-0.45%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$41.50 -0.09 (-0.22%) As of 06/13/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXEL Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period RHS Financial LLC Invests $435,000 in Exelixis, Inc. (NASDAQ:EXEL)RHS Financial LLC bought a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 11,778 shares of the biotechnology company's stock, valuedJune 15 at 8:53 AM | marketbeat.comNorthCrest Asset Manangement LLC Has $831,000 Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)NorthCrest Asset Manangement LLC increased its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 66.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,505 shares of theJune 15 at 4:49 AM | marketbeat.comExelixis (NASDAQ:EXEL) Stock Price Expected to Rise, HC Wainwright Analyst SaysJune 14 at 3:37 AM | americanbankingnews.comExelixis's SWOT analysis: cabozantinib's strength, zanzalintinib's potential drive stock outlookJune 14 at 12:57 AM | investing.comZacks.com featured highlights include Flex, CVS Health, Urban Outfitters and ExelixisJune 13 at 11:38 PM | uk.finance.yahoo.comExelixis, Inc. (NASDAQ:EXEL) Shares Acquired by Assenagon Asset Management S.A.Assenagon Asset Management S.A. increased its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 230.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 732,499 shares of the biotechnology company'sJune 13 at 4:35 AM | marketbeat.comHC Wainwright Increases Exelixis (NASDAQ:EXEL) Price Target to $47.00HC Wainwright boosted their price target on shares of Exelixis from $40.00 to $47.00 and gave the stock a "buy" rating in a research note on Thursday.June 12 at 8:30 AM | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Shares Bought by USA Financial FormulasUSA Financial Formulas boosted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 925.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,930 shares of the biotechnology company's stock after purchJune 11, 2025 | marketbeat.comSG Americas Securities LLC Grows Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)SG Americas Securities LLC boosted its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 4,857.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 567,653 shares of the biotechnology company's stockJune 11, 2025 | marketbeat.comFiduciary Financial Group LLC Invests $232,000 in Exelixis, Inc. (NASDAQ:EXEL)Fiduciary Financial Group LLC acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 6,746 shares of the biotechnology company's stock, valued at approximatelJune 11, 2025 | marketbeat.comPallas Capital Advisors LLC Grows Position in Exelixis, Inc. (NASDAQ:EXEL)Pallas Capital Advisors LLC raised its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 113.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 47,649 shares of the biotechnology compJune 10, 2025 | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Stock Holdings Increased by GAMMA Investing LLCGAMMA Investing LLC lifted its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 4,779.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 201,472 shares of the biotechnology company's stock afterJune 9, 2025 | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Shares Acquired by Merit Financial Group LLCMerit Financial Group LLC boosted its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 154.8% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 33,453 shares of the biotechnology company's stock after acquiring an addJune 8, 2025 | marketbeat.comZacks Research Forecasts Exelixis' Q2 Earnings (NASDAQ:EXEL)June 8, 2025 | americanbankingnews.comTourism information office project gets green light in PaphosJune 7, 2025 | msn.comTruist Financial Sticks to Its Buy Rating for Exelixis (EXEL)June 7, 2025 | theglobeandmail.comBrokerages Set Exelixis, Inc. (NASDAQ:EXEL) Price Target at $38.94June 7, 2025 | americanbankingnews.comZacks Research Estimates Exelixis' Q2 Earnings (NASDAQ:EXEL)Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Analysts at Zacks Research increased their Q2 2025 EPS estimates for Exelixis in a research note issued to investors on Tuesday, June 3rd. Zacks Research analyst E. Bagri now expects that the biotechnology company will post earnings of $0.52 per shareJune 6, 2025 | marketbeat.comBank of America Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) StockJune 6, 2025 | americanbankingnews.comWealth Enhancement Advisory Services LLC Sells 76,705 Shares of Exelixis, Inc. (NASDAQ:EXEL)Wealth Enhancement Advisory Services LLC decreased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 53.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 66,842 shares of the biotechnology companJune 6, 2025 | marketbeat.comBofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC CautionJune 5, 2025 | insidermonkey.comExelixis, Inc. (NASDAQ:EXEL) Director Sells 7,535 SharesExelixis, Inc. (NASDAQ:EXEL - Get Free Report) Director Jack L. Wyszomierski sold 7,535 shares of the company's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $43.09, for a total transaction of $324,683.15. Following the sale, the director now directly owns 358,882 shares of the company's stock, valued at approximately $15,464,225.38. This represents a 2.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.June 5, 2025 | marketbeat.comInsider Selling: Exelixis, Inc. (NASDAQ:EXEL) Director Sells 18,838 Shares of StockExelixis, Inc. (NASDAQ:EXEL - Get Free Report) Director Sue Gail Eckhardt sold 18,838 shares of the business's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $42.74, for a total value of $805,136.12. Following the completion of the sale, the director now owns 21,380 shares in the company, valued at approximately $913,781.20. The trade was a 46.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.June 5, 2025 | marketbeat.com4EXEL : Analyst Expectations For Exelixis's FutureJune 5, 2025 | benzinga.comExelixis (NASDAQ:EXEL) Price Target Raised to $46.00Bank of America lifted their target price on Exelixis from $45.00 to $46.00 and gave the stock a "neutral" rating in a report on Thursday.June 5, 2025 | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Director Sells $324,683.15 in StockJune 5, 2025 | insidertrades.comBofA Securities raises Exelixis stock price target to $46June 5, 2025 | investing.comAnalysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Agilent (A)June 5, 2025 | theglobeandmail.comRhumbline Advisers Sells 22,108 Shares of Exelixis, Inc. (NASDAQ:EXEL)Rhumbline Advisers cut its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 2.7% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 805,006 shares of the biotechnology company's stock after selling 22,1June 5, 2025 | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Shares Sold by Wellington Management Group LLPWellington Management Group LLP trimmed its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 43.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 138,408 shares of the biotechnology company's stock afJune 5, 2025 | marketbeat.comDirector Jack Wyszomierski Sells 7,535 Shares of Exelixis Inc (EXEL)June 4, 2025 | gurufocus.comExelixis, Inc. (NASDAQ:EXEL) Given Average Recommendation of "Hold" by BrokeragesExelixis, Inc. (NASDAQ:EXEL - Get Free Report) has earned a consensus recommendation of "Hold" from the nineteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and elevenJune 4, 2025 | marketbeat.comMilestone Asset Management LLC Has $313,000 Position in Exelixis, Inc. (NASDAQ:EXEL)Milestone Asset Management LLC lowered its position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 74.1% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,476 shares of the biotechnology company's stock after selling 24,301 shareJune 3, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Purchases New Position in Exelixis, Inc. (NASDAQ:EXEL)Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 360,292 shares of the biotechnology company'sJune 1, 2025 | marketbeat.comCalifornia State Teachers Retirement System Has $8.06 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)California State Teachers Retirement System trimmed its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 3.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 241,973 shares of the biotechnologyJune 1, 2025 | marketbeat.comPublic Employees Retirement System of Ohio Trims Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)Public Employees Retirement System of Ohio lowered its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 8.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 104,633 shares of the biotechnology company's stock afterJune 1, 2025 | marketbeat.com2 Top Stocks to Buy With Less Than $100May 30, 2025 | msn.com7,244 Shares in Exelixis, Inc. (NASDAQ:EXEL) Bought by Forum Financial Management LPForum Financial Management LP bought a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 7,244 shares of the biotechnology company's stock, valuMay 30, 2025 | marketbeat.comMackenzie Financial Corp Cuts Stake in Exelixis, Inc. (NASDAQ:EXEL)Mackenzie Financial Corp lessened its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 18.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 328,016 shares of the biotechnology company's stock after selling 75,5May 29, 2025 | marketbeat.comPhocas Financial Corp. Has $3.63 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)Phocas Financial Corp. trimmed its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 24.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 109,093 shares of the biotechnology company's stock after selling 35,689 shMay 28, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $28.12 Million Position in Exelixis, Inc. (NASDAQ:EXEL)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 4.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 844,345 shares of thMay 28, 2025 | marketbeat.comRoyal Bank of Canada Decreases Stake in Exelixis, Inc. (NASDAQ:EXEL)Royal Bank of Canada cut its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 26.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 453,142 shares of the biotechnology company's stock after sMay 28, 2025 | marketbeat.comGF Fund Management CO. LTD. Purchases Shares of 5,996 Exelixis, Inc. (NASDAQ:EXEL)GF Fund Management CO. LTD. acquired a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,996 shares of the biotechnology company's stoMay 27, 2025 | marketbeat.comQuantinno Capital Management LP Acquires New Shares in Exelixis, Inc. (NASDAQ:EXEL)Quantinno Capital Management LP acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 16,779 shares of the biotechnology company's stock, valued at approximaMay 27, 2025 | marketbeat.comNeo Ivy Capital Management Has $1.79 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL)Neo Ivy Capital Management grew its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 427.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 53,892 shares of the biotechnology company's stock after acquiriMay 26, 2025 | marketbeat.comJT Stratford LLC Takes $288,000 Position in Exelixis, Inc. (NASDAQ:EXEL)JT Stratford LLC purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 8,648 shares of the biotechnology company's stock, valued at approximately $2May 25, 2025 | marketbeat.com7,425 Shares in Exelixis, Inc. (NASDAQ:EXEL) Purchased by Worldquant Millennium Advisors LLCWorldquant Millennium Advisors LLC purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 7,425 shares of the bioteMay 25, 2025 | marketbeat.comExelixis's SWOT analysis: stock poised for growth amid oncology pipeline progressMay 25, 2025 | investing.comVoloridge Investment Management LLC Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL)Voloridge Investment Management LLC acquired a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 910,534 shares of the biotechnology company's stock, valued at approximatelyMay 24, 2025 | marketbeat.comTidal Investments LLC Grows Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)Tidal Investments LLC increased its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 187.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 104,665 shares of the biotechnology coMay 24, 2025 | marketbeat.com Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Email Address EXEL Media Mentions By Week EXEL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EXEL News Sentiment▼1.020.89▲Average Medical News Sentiment EXEL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EXEL Articles This Week▼1414▲EXEL Articles Average Week Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Biogen News United Therapeutics News Incyte News Neurocrine Biosciences News BioMarin Pharmaceutical News Exact Sciences News Repligen News Halozyme Therapeutics News Madrigal Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EXEL) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exelixis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exelixis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
